Glycoconjugate vaccines: an update

Bibliography

• Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009;374:903-11
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Immunization Data. 2014. Available from: http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf [Accessed 20 August 2014]
   Google Scholar
• World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age. 2008. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/ [Accessed 2 September 2014]
   Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012;799:1-20
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):B51-63
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012 – emerging needs and future perspectives. 2013. Available from: http://www.who.int/wer/2013/wer8812.pdf [Accessed 21 August 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Meningococcal Disease: Technical & Clinical Information. 2014. Available from: http://www.cdc.gov/meningococcal/clinical-info.html [Accessed 4 September 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal Disease. 2013. Available from: http://www.cdc.gov/pneumococcal/clinicians/clinical-features.html [Accessed 17 July 2014]
   Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398-412
   PubMed Web of Science ®Google Scholar
• Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011;7:170-82
   PubMed Web of Science ®Google Scholar
• Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31:3-14
   PubMed Web of Science ®Google Scholar
• Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64
   PubMed Web of Science ®Google Scholar
• Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005;72:2049-56
   PubMed Web of Science ®Google Scholar
• Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther 2013;13(1):11-33
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study Lancet. 2014;383:40-7
   Google Scholar
• Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995;269:496-512
   PubMed Web of Science ®Google Scholar
• Ryan KJ, Ray CG. Sherris medical microbiology. USA; McGraw Hill; 2004
   Google Scholar
• Ojo LR, O’Loughlin RE, Cohen AL, et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010;28:7117-22
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 1990;85:643-7
   PubMed Web of Science ®Google Scholar
• Collins S, Ramsay M, Campbell H, et al. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis 2013;57:1715-21
   PubMed Web of Science ®Google Scholar
• Hyunju L, Seokyung H, Lee HJ, Kim KH. Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean infants:a meta-analysis. J Korean Med Sci 2010;25(1):90-6
   PubMed Web of Science ®Google Scholar
• Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and Control of Haemophilus influenzae Type b Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2014. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6301a1.htm [Accessed 4 September 2014]
   Google Scholar
• Georges S, Lepoutre A, Dabernat H, Levy-Bruhl D. Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction. Epidemiol Infect 2013;141:1787-96
   PubMed Web of Science ®Google Scholar
• Public Health England. Haemophilus influenzae Epidemiological Data. Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/ [Accessed 4 September 2014]
   Google Scholar
• Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol 2011;49:3728-32
   PubMed Web of Science ®Google Scholar
• Heath PT, Bowen-Morris J, Griffiths D, et al. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997;77:488-92
   PubMed Web of Science ®Google Scholar
• Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009;49:372-80
   PubMed Web of Science ®Google Scholar
• Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012;34:385-99
   PubMed Web of Science ®Google Scholar
• McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521-3
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Invasive Haemophilus influenzae Type B disease in five young children–Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009;58(3):58-60
   PubMedGoogle Scholar
• McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004;329:655-8
   PubMed Web of Science ®Google Scholar
• Insel RA, Anderson PW. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol 1982;128:1267-70
   PubMedGoogle Scholar
• Nix EB, Hawdon N, Gravelle S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol 2012;19:766-71
   PubMed Web of Science ®Google Scholar
• Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010;28:4073-8
   PubMed Web of Science ®Google Scholar
• Giufrè M, Cardines R, Accogli M, et al. Identification of Haemophilus influenzae clones associated with invasive disease a decade after introduction of H. influenzae serotype b vaccination in Italy. Clin Vaccine Immunol 2013;20:1223-9
   PubMed Web of Science ®Google Scholar
• Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerg Infect Dis 2010;16:455-63
   PubMed Web of Science ®Google Scholar
• Bruce MG, Zulz T, DeByle C, et al. Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011. Emerg Infect Dis 2013;19:932-7
   PubMed Web of Science ®Google Scholar
• GAVI Alliance. Hib Initiative: a GAVI success story. 2011. Available from: http://www.gavi.org/library/news/roi/2010/hib-initiative–a-gavi-success-story/ [Accessed 3 July 2014]
   Google Scholar
• Griffiths UK, Clark A, Hajjeh R. Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants. J Pediatr 2013;163:S50-S9.e9
   PubMed Web of Science ®Google Scholar
• Vérez-Bencomo V, Fernández-Santana V, Ardí E, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;35:522
   Web of Science ®Google Scholar
• Torano G, Toledo ME, Baly A, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against haemophilus influenzae type b in human adult volunteers. Clin Vaccine Immunol 2006;13(9):1052-6
   PubMed Web of Science ®Google Scholar
• Metz JA, Hanieh S, Pradhan R, et al. Evaluation of Haemophilus influenzae type b vaccine for routine immunization in Nepali infants. Pediatr Infect Dis J 2012;31:e66-72
   PubMed Web of Science ®Google Scholar
• Cissé MF, Breugelmans JG, Bâ M, et al. The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 2010;29:499-503
   PubMed Web of Science ®Google Scholar
• Clark AD, Griffiths UK, Abbas SS, et al. Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India. J Pediatr 2013;163:S60-72
   PubMed Web of Science ®Google Scholar
• Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005;366:144-50
   PubMed Web of Science ®Google Scholar
• Oluwalana C, Howie SR, Secka O, et al. Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. J Pediatr 2013;163:S4-7
   PubMed Web of Science ®Google Scholar
• Fitzwater SP, Watt JP, Levine OS, Santosham M. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccin 2010;6:810-18
   PubMed Web of Science ®Google Scholar
• Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK - the impact of vaccination. J Med Microbiol 2011;60:1-8
   PubMed Web of Science ®Google Scholar
• Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011;29:8870-6
   PubMed Web of Science ®Google Scholar
• Austrian R. A brief history of pneumococcal vaccines. Drugs Aging 1999;15(Suppl 1):1-10
   PubMed Web of Science ®Google Scholar
• De Serres G, Pilishvili T, Link-Gelles R, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012;30:4067-72
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41
   PubMed Web of Science ®Google Scholar
• Kaye P, Malkani R, Martin S, et al. Invasive Pneumococcal Disease (IPD) in England and Wales after 7 -valent conjugate vaccine (PCV7); Potential impact of 10 and 13 valent vaccines. Presented at the 27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). 9 – 13 June 2009; Brussels, Belgium
   Google Scholar
• Leibovitz E. The effect of vaccination on Streptococcus pneumoniae resistance. Curr Infect Dis Rep 2008;10:182-91
   PubMedGoogle Scholar
• Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccine: PHiD-CV. Expert Rev Anti Infect Ther 2009;7:1063-74
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed). 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000973/human_med_001071.jsp&mid=WC0b01ac058001d124 [Accessed 16 June 2014]
   Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014;2:e397-405
   PubMed Web of Science ®Google Scholar
• Grant L, Burbidge P, Haston M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One 2013;8(9):e74906
   PubMed Web of Science ®Google Scholar
• Bieging KT, Rajam G, Holder P, et al. Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol 2005;12:1238-42
   PubMedGoogle Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28:S66-76
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014;11:e1001657
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381:214-22
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8
   PubMed Web of Science ®Google Scholar
• Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009;28:71-8
   PubMed Web of Science ®Google Scholar
• Jefferies JM, Macdonald E, Faust SN, Clarke SC. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin 2011;7:1012-18
   PubMed Web of Science ®Google Scholar
• Wyeth Pharmaceutical. PREVNAR 13, Product specifications booklet. 2014. Available from: http://labeling.pfizer.com/showlabeling.aspx?id=501 [Accessed 3 September 2014]
   Google Scholar
• Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010;126:e493-505
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010;17:1017-26
   PubMed Web of Science ®Google Scholar
• Bryant KA, Block SL, Baker SA, Group PCVIS. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010;125:866-75
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28:4192-203
   PubMed Web of Science ®Google Scholar
• Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013;59:778-88
   PubMed Web of Science ®Google Scholar
• Public Health England. Numbers of laboratory confirmed invasive pneumococcal disease cases by age group, in England and Wales, 1996-2005. 2008. Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDGraphs/pneumoNumberLabConfirmedAgeSpecific/ [Accessed 13 August 2014]
   Google Scholar
• 13-valent pneumococcal conjugate vaccine. Prescrire Int 2011;20(112):5-7; 9
   PubMedGoogle Scholar
• Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine 2013;31:5289-95
   PubMed Web of Science ®Google Scholar
• Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine 2014;32:2022-6
   PubMed Web of Science ®Google Scholar
• Alicino C, Barberis I, Orsi A, Durando P. Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 - valent polysaccharide conjugate vaccine. Minerva Med 2014;105:89-97
   Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-84
   PubMed Web of Science ®Google Scholar
• FDA. PREVNAR 13 VRBPAC Adult Indication Briefing Document. 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf [Accessed 5 September 2014]
   Google Scholar
• Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-35
   PubMed Web of Science ®Google Scholar
• Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009;49:e23-9
   PubMed Web of Science ®Google Scholar
• Mitchell R, Trück J, Pollard AJ. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. Expert Opin Biol Ther 2013;13:1451-65
   PubMed Web of Science ®Google Scholar
• Frenck R, Thompson A, Senders S, et al. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014;33:183-9
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1-18
   PubMedGoogle Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine Preventable Diseases. 2012. Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/front-portion.pdf [Accessed 28 August 2014]
   Google Scholar
• Bryant K, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18–49 years, naïve to 23-valent pneumococcal polysaccharide vaccine. Presented at the 23rd ECCMID (European Society of Clinical Microbiology and Infectious Diseases). 27 – 30th April 2013; Berlin
   Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010;14:e197-209
   PubMed Web of Science ®Google Scholar
• van der Linden M, Reinert RR, Kern WV, Imöhl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis 2013;13:70
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis 2012;12:101
   PubMed Web of Science ®Google Scholar
• Martí SG, Colantonio L, Bardach A, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc 2013;11:21
   PubMedGoogle Scholar
• McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011;10:109-29
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Alderson MR. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011;47(3):207-14
   PubMed Web of Science ®Google Scholar
• Cao J, Chen D, Xu W, et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 2007;25:4996-5005
   PubMed Web of Science ®Google Scholar
• Cao J, Li D, Gong Y, et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 2009;156:52-60
   PubMed Web of Science ®Google Scholar
• Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine 2014;32:3025-34
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Armah GE, Madhi SA, et al. The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative. Pan Afr Med J 2011;8:24
   PubMedGoogle Scholar
• UNICEF/WHO. Expanding immunization coverage. 2011. Available from: http://www.unicef.org/immunization/index_coverage.html [Accessed 4 September 2014]
   Google Scholar
• GAVI Alliance. Advance Market Commitment for Pneumococcal Vaccines 2014. Available from: http://www.gavi.org/search/?SearchText=%20Pneumococcal%20AMC%20annual%20report [Accessed 9 September]
   Google Scholar
• HealthyPeople.gov. Immunization and Infectious Diseases. 2014. Available from: http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=23 [Accessed 3 July 2014]
   Google Scholar
• Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA 2013;110:19077-82
   PubMed Web of Science ®Google Scholar
• Borrow R, Abad R, Trotter C, et al. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013;31:4477-86
   PubMed Web of Science ®Google Scholar
• Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother 2013;9:162-71
   PubMed Web of Science ®Google Scholar
• Bröker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother 2012;8:1907-11
   PubMed Web of Science ®Google Scholar
• Novartis Vaccines and Diagnostics S.r.l. MENVEO, Product specifications booklet. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf [Accessed 1 September 2014]
   Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6
   PubMed Web of Science ®Google Scholar
• Public Health England. Meningococcal disease: laboratory confirmed cases in England and Wales. 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/343375/Table_1a_Invasive_meningococcal__E_W_by_capsular_group___epi_year.pdf [Accessed 20 August 2014]
   Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, García M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005;23:4097-100
   PubMed Web of Science ®Google Scholar
• Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 2006;11:E060302.4
   PubMedGoogle Scholar
• Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-7
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. Pediatr Infect Dis J 2012;31:616-22
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006;43:1387-94
   PubMed Web of Science ®Google Scholar
• McVernon J, Maclennan J, Buttery J, et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002;21:747-53
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91
   PubMed Web of Science ®Google Scholar
• Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010;50(12):1601-10
   PubMed Web of Science ®Google Scholar
• Public Health England. Meningococcal C Conjugate Vaccine – Information about the ‘freshers’ dose. 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/298443/MenC_vaccine_for_new_uni_students_March2014.pdf [Accessed 3 September 2014]
   Google Scholar
• de Whalley PC, Snape MD, Plested E, et al. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child 2013;98:686-91
   PubMed Web of Science ®Google Scholar
• Stoof SP, van der Klis FR, van Rooijen DM, et al. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers. PLoS One 2014;9:e100651
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Infant Meningococcal Vaccination: advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. 2013. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm [Accessed 4 September 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2013. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm [Accessed 2 September 2014]
   Google Scholar
• Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011;128(6):1213-18
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network Neisseria meningitidis 2012. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/mening12.html [Accessed 18 August 2014]
   Google Scholar
• Ramsay M, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997;7:R49-54
   PubMedGoogle Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-91
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals. MenHibrix, Product specifications booklet. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm308577.pdf [Accessed 8 June 2014]
   Google Scholar
• Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011;127:e1375-85
   PubMedGoogle Scholar
• Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010;29:48-52
   PubMedGoogle Scholar
• Nimenrix. Summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/26514 [Accessed 17 November 2014]
   Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011;29:4264-73
   PubMed Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013;13:116
   PubMed Web of Science ®Google Scholar
• Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr 2013;172:601-12
   PubMed Web of Science ®Google Scholar
• Østergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013;17:e173-6
   PubMed Web of Science ®Google Scholar
• Hedari C, Khinkarly RW, Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 2014;7:85-99
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013;56:354-63
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Ba AK, Sanou I, et al. Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis 2013;13:363
   PubMed Web of Science ®Google Scholar
• Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304
   PubMed Web of Science ®Google Scholar
• Zipursky S, Djingarey MH, Lodjo JC, et al. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014;32:1431-5
   PubMed Web of Science ®Google Scholar
• Savage N. Logistics: Keeping cool: Nature, international weekly journal of science. 2014. Available from: http://www.nature.com/nature/journal/v507/n7490_supp/full/507S8a.html [Accessed 2 September 2014]
   Google Scholar
• Collard JM, Issaka B, Zaneidou M, et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis 2013;13:576
   PubMed Web of Science ®Google Scholar
• Nicolas P, Décousset L, Riglet V, et al. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001;7:849-54
   PubMed Web of Science ®Google Scholar
• Nicolas P, Norheim G, Garnotel E, et al. Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129-35
   PubMed Web of Science ®Google Scholar
• Delrieu I, Yaro S, Tamekloé TA, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011;6:e19513
   PubMed Web of Science ®Google Scholar
• Glassman M, Duran D, Sumner A. Global Health and the New Bottom Billion: How Funders Should Respond to Shifts in Global Poverty and Disease Burden. 2012. Available from: http://www.cgdev.org/doc/full_text/BottomBillion/Glassman_Bottom_Billion.html [Accessed 2 September 2014]
   Google Scholar
• Berkley S. Improving access to vaccines through tiered pricing. Lancet 2014;383:2265-7
   PubMed Web of Science ®Google Scholar
• UNICEF. Ukraine Statistics. 2013. Available from: http://www.unicef.org/infobycountry/ukraine_statistics.html [Accessed 30 August 2014]
   Google Scholar
• UNICEF. Egypt Statistics. 2013. Available from: http://www.unicef.org/infobycountry/egypt_statistics.html [Accessed 4 September 2014]
   Google Scholar
• UNICEF. Syria Statistics. 2013. Available from: http://www.unicef.org/infobycountry/syria_statistics.html [Accessed 4 September 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Measles Cases and Outbreaks. 2014. Available from: http://www.cdc.gov/measles/cases-outbreaks.html [Accessed 3 September 2014]
   Google Scholar
• The Lancet Infectious Diseases. A wake-up call for polio eradication 2014. Available from: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70368-2/fulltext%3Felsca1%3DETOC-TLID%26elsca2%3Demail%26elsca3%3DHTDJ [Accessed 4 September 2014]
   Google Scholar
• Sharma SK, Roumanes D, Almudevar A, et al. CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine 2013;31:3090-7
   PubMed Web of Science ®Google Scholar
• Musher DM. Pneumococcal vaccine–direct and indirect ("herd") effects. N Engl J Med 2006;354:1522-4
   PubMed Web of Science ®Google Scholar
• Tsang R. Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect Dis 2007;7:569-70
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Gray S, et al. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006;6:616-17; author reply 7-8
   PubMed Web of Science ®Google Scholar
• Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005;41:30-4
   Google Scholar
• Roderick M, Finn A. Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect 2014;68(Suppl 1):S76-82
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2014 global summary. 2014. Available from: http://apps.who.int/immunization_monitoring/globalsummary [Accessed 4 September 2014]
   Google Scholar
• Johns Hopkins Bloomberg School of Public Health. VIMS Report: global Vaccine Introduction. 2013. Available from: http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/IVAC-VIMS-Report-2013-06.pdf [Accessed 9 August 2014]
   Google Scholar